Recursion Pharmaceuticals and Sarepta Therapeutics underperform broader markets, with fundamentals failing to justify current valuations.
Recursion Pharmaceuticals (NASDAQ: RXRX) and Sarepta Therapeutics (NASDAQ: SRPT) continue to lag broader equities, despite recent pullbacks drawing investor interest. Analysts caution that structural challenges may outweigh near-term rebound potential for both stocks.
RXRX, which leverages AI for drug discovery, faces rising costs and extended timelines in clinical trials, despite progress on candidates like REC-4881 for familial adenomatous polyposis. Sarepta’s gene therapy pipeline has similarly struggled to outpace market expectations, with regulatory hurdles adding uncertainty.
Both stocks have underperformed the NASDAQ year-to-date, reflecting skepticism over their ability to deliver sustainable growth. Valuations remain elevated relative to pipeline maturity, limiting upside potential.